Malaria vaccine shows promise — now come tougher trials

Ledford, Heidi

doi:10.1038/d41586-021-01096-7

Cited by 9 publications

(4 citation statements)

References 1 publication

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Purification by flash silica gel chromatography (CH 2 Cl 2 /MeOH 1:0 to 97:3) gave rise to the desired product as white foam. (2,cyclopentyl acetate (±)-4a. The product was obtained (1.15 g, 70%) according to the Protocol A using compound (±)-3 (1 g).…”

Section: Protocol a (Mitsunobu Conditions For Nucleobase Coupling)mentioning

confidence: 99%

“…In 2021, the WHO estimated the number of malaria deaths at 619 000 and 247 million cases of malaria worldwide, the latter having increased for the second consecutive year [1]. In October 2021, the RTS,S (Mosquirix®) malaria vaccine was approved and recommended by the WHO for children in sub-Saharan Africa and in other regions with moderate to high P. falciparum malaria transmission [1,2]. Unfortunately, the vaccine has a limited efficacy [3] and treatment is still complicated by the emergence of drug resistance [4] and the development of new drugs is urgently required.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Purine containing carbonucleoside phosphonate analogues as novel chemotype for Plasmodium falciparum Inhibition

Mohamed

Wein

Uttaro

et al. 2023

European Journal of Medicinal Chemistry

View full text Add to dashboard Cite

Section: Protocol a (Mitsunobu Conditions For Nucleobase Coupling)mentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Purine containing carbonucleoside phosphonate analogues as novel chemotype for Plasmodium falciparum Inhibition

Mohamed

Wein

Uttaro

et al. 2023

European Journal of Medicinal Chemistry

View full text Add to dashboard Cite

“…In 2019, the number of malaria cases is reported to have exceeded 220 million causing 400,000 deaths, mostly in Africa [1,2]. While an efficacious vaccine is reported to be underway [3], chemical therapies remain the main methods to reduce the burden of malaria. Nowadays, due to malaria resistance to existing drugs, the only WHO-recommended first-line treatments are five artemisininbased combination therapies (ACTs) [4].…”

Section: Introductionmentioning

confidence: 99%

Antimalarial Inhibitors Targeting Epigenetics or Mitochondria in Plasmodium falciparum: Recent Survey upon Synthesis and Biological Evaluation of Potential Drugs against Malaria

et al. 2021

View full text Add to dashboard Cite

Despite many efforts, malaria remains among the most problematic infectious diseases worldwide, mainly due to the development of drug resistance by P. falciparum. Over the past decade, new essential pathways have been emerged to fight against malaria. Among them, epigenetic processes and mitochondrial metabolism appear to be important targets. This review will focus on recent evolutions concerning worldwide efforts to conceive, synthesize and evaluate new drug candidates interfering selectively and efficiently with these two targets and pathways. The focus will be on compounds/scaffolds that possess biological/pharmacophoric properties on DNA methyltransferases and HDAC’s for epigenetics, and on cytochrome bc1 and dihydroorotate dehydrogenase for mitochondrion.

show abstract

“…Among all the antiprotozoal vaccines available, the anticoccidial vaccines for poultry are well developed. By contrast, no vaccine is available for protozoal diseases of humans [19,20], with the exception of two candidates for malaria, with promising results in early clinical trials [21][22][23].…”

Section: Introductionmentioning

confidence: 99%

Sexual Development in Non-Human Parasitic Apicomplexa: Just Biology or Targets for Control?

Cruz‐Bustos

Feix

Ruttkowski

et al. 2021

Animals

View full text Add to dashboard Cite

The phylum Apicomplexa is a major group of protozoan parasites including gregarines, coccidia, haemogregarines, haemosporidia and piroplasms, with more than 6000 named species. Three of these subgroups, the coccidia, hemosporidia, and piroplasms, contain parasites that cause important diseases of humans and animals worldwide. All of them have complex life cycles involving a switch between asexual and sexual reproduction, which is key to their development. Fertilization (i.e., fusion of female and male cells) results in the formation of a zygote that undergoes meiosis, forming a new generation of asexual stages. In eukaryotes, sexual reproduction is the predominant mode of recombination and segregation of DNA. Sex is well documented in many protist groups, and together with meiosis, is frequently linked with transmission to new hosts. Apicomplexan sexual stages constitute a bottleneck in the life cycle of these parasites, as they are obligatory for the development of new transmissible stages. Consequently, the sexual stages represent attractive targets for vaccination. Detailed understanding of apicomplexan sexual biology will pave the way for the design and implementation of effective transmission-blocking strategies for parasite control. This article reviews the current knowledge on the sexual development of Apicomplexa and the progress in transmission-blocking vaccines for their control, their advantages and limitations and outstanding questions for the future.

show abstract

Malaria vaccine shows promise — now come tougher trials

Cited by 9 publications

References 1 publication

Purine containing carbonucleoside phosphonate analogues as novel chemotype for Plasmodium falciparum Inhibition

Purine containing carbonucleoside phosphonate analogues as novel chemotype for Plasmodium falciparum Inhibition

Antimalarial Inhibitors Targeting Epigenetics or Mitochondria in Plasmodium falciparum: Recent Survey upon Synthesis and Biological Evaluation of Potential Drugs against Malaria

Sexual Development in Non-Human Parasitic Apicomplexa: Just Biology or Targets for Control?

Contact Info

Product

Resources

About